The importance of VHTs is found in their potential to foster and accelerate the development of integrated, validated digital representations of the human body. This concept is being brought forth for example by edith-csa.eu and virtualhumantwins.eu, whose we are supporters. Our focus is personalized and precision care in oncology, current key priorities for the European Union.
The exercise of a oncological VHT can help predict how a patient might respond to different treatment options. This approach helps doctors choose therapies with the highest efficacy and lowest risk of side effects for each individual. Moreover, based on the expression of given biomarkers linked to molecular signature of the tumor, doctors can virtually select and try therapies that are most likely to be effective against that specific cancer subtype.
Personalized and precision care in oncology will accelerate tangible benefits for citizens and patients, promoting NHS saving and burden reduction, while supporting EU science and technology. Being built to mimic and predict the behavior of breast cancer physical counterparts, CancerMate has been purposely designed to transfer the research experience behind it, to clinical research and practice framework. In fact, the PDEs system structure on which the method is built upon, ensures that 3D interactive visualizations can be provided with few additional data manipulations, to match with the underlying mathematics of proliferation.
A few metrics to help framing the importance of oncology industry in Europe:
- Europe Oncology Market size surpassed USD 79 billion in 2022
- Solid tumors represent approximatively 90% of adult human cancers
- Expected CAGR in the European Oncology Market through 2022-2028